New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C - Episode 8

New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C

On February 3, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of lung cancer to participate in a virtual workshop to discuss the emerging treatment landscape of targeted therapies in NSCLC. This article summarizes key data about KRAS G12C as a therapeutic target as well as insights from stakeholder discussions regarding this topic.

EP. 1: Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer
EP. 2: Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer
EP. 3: Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer
EP. 4: Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer
EP. 5: Dr. Hanna on Approaching Biomarker Testing in Lung Cancer
EP. 6: Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer
EP. 7: Dr. Boyle on Approaching Biomarker Testing in Lung Cancer
Now Viewing
EP. 8: New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12C

Related Content:

New Therapeutic Targets in Non–Small Cell Lung Cancer: KRAS G12CLung Cancer
Dr Gadgeel on Longer-Term Data for Amivantamab Plus Lazertinib in EGFR+ NSCLC
Dr Sands on Consolidation Durvalumab as a Potential New SOC for LS-SCLC After Chemoradiation
FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation